DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes

Ann N Y Acad Sci. 2006 Oct;1079:340-4. doi: 10.1196/annals.1375.052.

Abstract

DiaPep277 is an immunomodulatory peptide that arrests beta cell destruction in mouse models of type 1 diabetes mellitus (T1DM). This article extends an original pilot observation to two studies of 61 patients (age > 16 years), diagnosed with T1DM within 6 months, and with measurable beta cell function. Patients were treated with placebo (n = 27) or 1.0 mg DiaPep277 (n = 34). After 13 months, 1.0 mg Dia Pep277 treatment significantly (P = 0.02) preserved beta cell function as compared to the control with a trend for reduced HbA1c. This was achieved without an increase in insulin dose in the DiaPep277 group and with excellent safety. DiaPep277-treated patients also had fewer Th1 DiaPep277-specific T cells.

Publication types

  • Clinical Trial

MeSH terms

  • Amino Acid Sequence
  • Area Under Curve
  • C-Peptide / blood
  • Chaperonin 60
  • Diabetes Mellitus, Type 1 / blood
  • Diabetes Mellitus, Type 1 / diagnosis
  • Diabetes Mellitus, Type 1 / drug therapy*
  • Diabetes Mellitus, Type 1 / immunology
  • Female
  • Follow-Up Studies
  • Glycated Hemoglobin A / analysis
  • Humans
  • Hypoglycemic Agents / metabolism*
  • Insulin / biosynthesis*
  • Insulin-Secreting Cells / metabolism
  • Male
  • Molecular Sequence Data
  • Peptide Fragments / adverse effects
  • Peptide Fragments / chemistry
  • Peptide Fragments / therapeutic use*
  • Peptides / adverse effects
  • Peptides / chemistry
  • Peptides / therapeutic use*
  • Time Factors
  • Treatment Outcome

Substances

  • C-Peptide
  • Chaperonin 60
  • DiaPep 277
  • Glycated Hemoglobin A
  • Hypoglycemic Agents
  • Insulin
  • Peptide Fragments
  • Peptides